Clinical Trial Update: Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluated the combination of nivolumab with a PD-L1/IDO peptide vaccine in patients with metastatic melanoma. The trial has completed and resu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• PD-L1/IDO peptide vaccine (PD-L1/IDO peptide vaccine)
• nivolumab (nivolumab)

Snippet

Sponsor: Inge Marie Svane | Conditions: Metastatic Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-02-20